UK's GSK announces $30 billion U.S. pharma investment amid Trump state visit
British pharmaceutical giant GSK committed to investing at least $30 billion in U.S. research and developing and manufacturing over the next five years.
Predicted Price is the pryogiTM prediction of where the price is going in next 3-4 quarters. There may be a revision of the predicted price every 3 months from the date of publication of the first predicted price of the stock. Price on Report Date is the price of the stock on the day prediction was published by pryogiTM. Current price shows the current price of the stock.
Margin of error shows range the price will end up in dollars either above or below the predicted price. Margin of error percentage shows the price will end up in percentage either above or below the predicted price.
Expected Returns from report date shows the returns (positive or negative) from published prediction date if you bought the stock on report date. Expected Returns from today shows the returns from today if you buy the stock today. A positive expected returns indicates a profit you will make, a negative expected return indicates a loss you will make if you buy the stock. There are different strategies to apply in the stock market for profit and loss, pryogiTM will publish such strategies in the future to help you.
PryogiTM meter shows you predicted price, price on the date this prediction was published(report date) and price of the stock today on a price scale. This indicates if the stock price is moving towards or away from the predicted price
PryogiTM performance chart shows actual movement of stock price from prediction published date(report date) and if the price is moving towards or away from predicted price
British pharmaceutical giant GSK committed to investing at least $30 billion in U.S. research and developing and manufacturing over the next five years.
2025 Half-Year Results and Business Update ...
Smart Beta ETF report for ...
The global market for medications addressing psychotic disorders is projected to reach $32.1 billion by 2033, exhibiting a robust compound annual growth rate ( CAGR ) of 6.5% over the forecast period.
Dividend-paying growth stocks and covered call ETFs provide opportunities to generate income even in a declining stock market.
The six-part special edition series of "I'm Aware That I'm Rare: the phaware® podcast" tackles stigma, science, and survival in one of the fastest-rising causes of pulmonary hypertension in the U.S.
Intuitive Surgical shares are down 13% in three months as margin pressures weigh on the stock, but strong procedure growth keeps its long-term story intact.
The answer might surprise you.
An unbeatable advantage makes this stock a popular one among billionaire investors.
J&J seeks EMA's nod to icotrokinra for treating plaque psoriasis in adults and pediatric patients aged 12 years and older.
J&J shares are up over 23% year-to-date despite ongoing talc-related lawsuits. Its medical device segment, especially cardiovascular care, is driving steady growth. Want to trade this news? Get access to the 34-0 income strategy that loves volatility →
ABBV secures Rinvoq's market lead until 2037, boosting shares as strong sales and new indications fuel long-term growth prospects.
Black Diamond sharpens focus on silevertinib after outlicensing BDTX-4933, cutting costs, and securing cash runway into late 2027.
These ETFs can be complementary pieces in many investors' portfolios.
The Vanguard High Dividend Yield Index Fund ETF is a low-cost fund that holds nearly 600 stocks and yields 2.5%.
In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $178.41, denoting a +1.49% move from the preceding trading day.
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Big Pharma faces tariff risks, patent cliffs, and regulatory pressure, but innovation and strong pipelines keep Eli Lilly, J&J, Novartis, Pfizer, and Bayer in focus.
In the Large-Cap Pharmaceuticals industry, Lilly, J&J, Novartis, Pfizer and Bayer are worth retaining amid macro pressure and rising innovation.
J&J secures FDA approval for Inlexzoh, which boosts its Innovative Medicine pipeline and reinforces long-term growth momentum.
Zacks highlights Johnson & Johnson, SAP, Coca-Cola, Hamilton Beach, and SIFCO Industries in its latest research roundup, showcasing both blue-chip resilience and micro-cap growth stories.
Appointments strengthen Picard's Board with proven expertise in capital markets and global MedTech leadership Appointments strengthen Picard's Board with proven expertise in capital markets and global MedTech leadership ...
You can have the best of both worlds with this ETF.
Johnson & Johnson's JNJ short percent of float has risen 8.45% since its last report. The company recently reported that it has 18.52 million shares sold short, which is 0.77% of all regular shares that are available for trading.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
About $350 billion U.S. biotech investments point to long-term upside in pharma ETFs and domestic growth stocks. J&J, Novartis, Eli Lilly, AstraZeneca, and BMS are leading expansions creating thousands of jobs. Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly Loading Up On
HOUSTON, Sept. 09, 2025 ( GLOBE NEWSWIRE ) -- Salarius Pharmaceuticals, Inc. SLRX ( Salarius or the Company ) announces that on September 4, 2025 the Company received notification from The Nasdaq Stock Market LLC ( Nasdaq ) that it has regained compliance with Listing Rule 5550 ( a ) ( 2 ) , the ...
HOUSTON, Sept. 09, 2025 ( GLOBE NEWSWIRE ) -- Salarius Pharmaceuticals, Inc. ( Nasdaq: SLRX ) ( Salarius or the Company ) announces that on September 4, 2025 the Company received notification from The Nasdaq Stock Market LLC ( Nasdaq ) that it has regained compliance with Listing Rule 5550 ( a ) ...
Newly released data shows that nine in ten babies lack critical gut microbes needed for healthy development. Persephone's Daily Synergistic Synbiotic, built on the largest and most comprehensive U.S. infant gut microbiome study, can help restore them.
Style Box ETF report for ...
ABBV and JNJ face patent cliffs but show resilience with strong pipelines, acquisitions and promising growth drivers.
Zacks highlights Hecla Mining, GE Aerospace, and Stride as standout performers in a volatile market, driven by earnings trends and stock upgrades.
What does the future hold for Johnson & Johnson? In this episode, we break down the company's strengths, challenges, and what investors can expect moving forward.
In the current market session, Johnson & Johnson Inc. JNJ stock price is at $177.33, after a 0.80% drop. However, over the past month, the company's stock spiked by 2.31%, and in the past year, by 6.43%.
Black Diamond shines with a 51.1% stock surge, fueled by silevertinib's progress and pipeline momentum in oncology.
Black Diamond focuses on silevertinib for NSCLC and GBM, with key trial readouts due in late 2025 and FDA feedback expected in 2026.
ABBV's expanding neuroscience portfolio, led by Botox, Vraylar and new launches like Vyalev, continues to fuel top-line growth.
There is more to like than the dividend with these companies.
JNJ believes 10 of its new products and pipeline candidates can deliver peak sales of $5 billion, including Talvey, Tecvayli, Imaavy, Caplyta and others.
LAS VEGAS, Sept. 03, 2025 ( GLOBE NEWSWIRE ) -- Live Ventures Incorporated LIVE, a diversified holding company that focuses on value-oriented acquisitions of domestic middle-market companies, today announced a strategic campaign to tell its story more fully and frequently to all stakeholders. ...
LAS VEGAS, Sept. 03, 2025 ( GLOBE NEWSWIRE ) -- Live Ventures Incorporated ( Nasdaq: LIVE ) , a diversified holding company that focuses on value-oriented acquisitions of domestic middle-market companies, today announced a strategic campaign to tell its story more fully and frequently to all ...
MENLO PARK, Calif., Sept. 02, 2025 ( GLOBE NEWSWIRE ) -- Sight Sciences, Inc.
VARIPULSE achieved 99.7% acute effectiveness and zero strokes in AF patients, per ESC Congress data. Johnson & Johnson stock is up 0.53% at $178.11 at the last check on Tuesday, and up 23.67% year to date. Johnson & Johnson JNJ reported new cardiovascular data at the 2025 European Society of ...
GKOS raises revenue guidance after record 1H sales, fueled by iDose TR adoption and expanding international glaucoma momentum.